A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection.
Tegveer SandhuArlene TiengSridhar ChilimuriGiovanni FranchinPublished in: The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale (2020)
Our study demonstrates that colchicine improved outcomes in patients with COVID-19 receiving standard of care therapy. Future randomized, placebo-controlled clinical trials to assess the potential benefit of colchicine in COVID-19 are warranted.
Keyphrases
- placebo controlled
- double blind
- clinical trial
- phase ii
- phase iii
- healthcare
- open label
- coronavirus disease
- sars cov
- palliative care
- study protocol
- early onset
- phase ii study
- emergency department
- high intensity
- current status
- adipose tissue
- radiation therapy
- adverse drug
- cell therapy
- health insurance
- mesenchymal stem cells
- rectal cancer
- insulin resistance
- climate change
- skeletal muscle
- replacement therapy